about
Prevalence and correlates of antipsychotic polypharmacy in children and adolescents receiving antipsychotic treatmentOutcomes of nonsurgical management and efficacy of demecarium bromide treatment for primary lens instability in dogs: 34 cases (1990-2004)Pharmacoepidemiology of antipsychotic use in youth with ADHD: trends and clinical implicationsCardiovascular safety of central nervous system stimulants in children and adolescents: population based cohort studyComparative adherence to diabetes drugs: An analysis of electronic health records and claims data.Stimulants and cardiovascular events in youth with attention-deficit/hyperactivity disorderBroadened use of atypical antipsychotics: safety, effectiveness, and policy challenges.Instrumental variable applications using nursing home prescribing preferences in comparative effectiveness researchComparing marginal structural models to standard methods for estimating treatment effects of antihypertensive combination therapyAntipsychotics and mortality: adjusting for mortality risk scores to address confounding by terminal illness.Comparison of different approaches to confounding adjustment in a study on the association of antipsychotic medication with mortality in older nursing home patients.Validation of a claims-based antipsychotic polypharmacy measureFoster care, externalizing disorders, and antipsychotic use among Medicaid-enrolled youths.Comparative effectiveness of second-generation antipsychotic medications in early-onset schizophreniaAgreement and validity of electronic health record prescribing data relative to pharmacy claims data: A validation study from a US electronic health record database.Risk of Suicidal Events With Atomoxetine Compared to Stimulant Treatment: A Cohort Study.Alpha-adducin polymorphism associated with increased risk of adverse cardiovascular outcomes: results from GENEtic Substudy of the INternational VErapamil SR-trandolapril STudy (INVEST-GENES).Prescribing of psychotropic medications to children and adolescents: quo vadis?Pre-existing cardiovascular conditions and pharmacological treatment of adult ADHD.Assessing medication exposures and outcomes in the frail elderly: assessing research challenges in nursing home pharmacotherapy.Variation in antipsychotic treatment choice across US nursing homes.The incident user design in comparative effectiveness research.The Asian Pharmacoepidemiology Network (AsPEN): promoting multi-national collaboration for pharmacoepidemiologic research in Asia.Geographic and clinical variation in clozapine use in the United States.Antipsychotic medication use in nursing homes: a proposed measure of quality.Antipsychotic Medication Treatment Patterns in Adult Depression.Type 2 Diabetes Mellitus in Youth Exposed to Antipsychotics: A Systematic Review and Meta-analysis.Antipsychotic Use Trends in Youth With Autism Spectrum Disorder and/or Intellectual Disability: A Meta-Analysis.Suicide Following Deliberate Self-Harm.Extent, Time Course, and Moderators of Antipsychotic Treatment in Youth With Mood Disorders: Results of a Meta-Analysis and Meta-Regression Analyses.Short-term Suicide Risk After Psychiatric Hospital Discharge.Distinct Visual Processing of Real Objects and Pictures of Those Objects in 7- to 9-month-old Infants.Trends in antipsychotic drug use by very young, privately insured children.Impact of the black triangle label on prescribing of new drugs in the United Kingdom: lessons for the United States at a time of deregulation.Comparative Effectiveness of Clozapine and Standard Antipsychotic Treatment in Adults With Schizophrenia.Clozapine for Schizophrenia: State Variation in Evidence-Based Practice.Premature Mortality Among Adults With Schizophrenia in the United States.Re-examining antidepressant risk of self-injury in children and adolescents.Cardiac safety of central nervous system stimulants in children and adolescents with attention-deficit/hyperactivity disorder.Multi-country rapid adverse drug event assessment: the Asian Pharmacoepidemiology Network (AsPEN) antipsychotic and acute hyperglycaemia study.
P50
Q27028197-36872E41-2D78-49EA-A4F2-F4DA1147A780Q28235046-5336842C-3DED-4A4F-A66E-80C1D080A28EQ28295134-80CBA548-349A-4E16-824C-B913585DDDD4Q28729087-932A45D4-C86A-44B0-90D9-366F9390A730Q31171523-87FBCDA0-0AA4-4B41-A6E3-7DD0F5659D8FQ33160890-414905C2-1F8E-42F5-83DB-EC33496A2E5DQ33960193-A9A33802-36F0-4442-BE3B-881A7D126D94Q33976565-455AAF14-7BE2-4D85-9393-FC4A63518F5BQ34367324-33BCB5CB-A10C-4EB5-A390-DBB43F38E89DQ35217862-03F214E6-70E9-4F1C-8B34-11AC0B2C54BDQ35627432-D45B971B-0EFB-415D-8B77-B059AAA78E4AQ35801221-01AE4DF2-4340-4C8A-85C2-C0B4A3455780Q35809854-E4710397-E89B-4509-96E6-607F514B407FQ36121469-EE2A3532-A012-416B-9DEA-5151132799DBQ36400213-4A266439-3409-4C11-AD69-4528C881DAD7Q36838216-9B18D146-28C3-4DC5-8791-291C779034B8Q36899357-730DD38C-809A-43F7-905A-3251253FFAB6Q36930857-E51B7899-D8A4-4C58-91A6-1B83B603E3DBQ37709983-E0494497-2CE1-4343-B7A2-79D2E879C540Q37753922-22997D29-BF9E-4124-8D3A-D9F0C81A4116Q37971298-61CD6999-AC56-4BCA-A18E-11187FDBDCAAQ38048231-E9ACCF06-7877-4CD2-B22D-1E855405A631Q38105056-796DA00B-E8BC-43FF-AE92-36223A220084Q38162752-CBB0F4BB-905A-404E-BA4A-245CAF8F107AQ38197557-86D1920B-735A-4C36-A9D3-B2368DF6624EQ38689268-BFA68C72-CBE1-491F-B6EF-786ED0DF11F2Q38705205-A7734A45-93E9-4225-9349-EAECB658B22CQ38847674-B77575B2-082E-4FB7-9181-33C48EDAA6CAQ38893058-B39BD67D-EFE0-42B9-AAF4-187D3EEA7913Q39031507-2F353287-EA08-46C6-810F-CB3334A5E039Q39365917-AB65B130-1D8E-43D1-B2E7-DB7E2EA6EDC6Q39631352-917F8EA5-729A-435B-87B6-E83C3E312B24Q39893516-2EA0074A-2B62-491B-A28A-6B3BBEF3C3B8Q40063546-E232A69D-21AE-404E-A380-113F32626EA8Q40351255-812ED5F0-FF76-4139-B4E7-2EABDDEF5D6FQ40368980-7410FC57-7351-4761-9509-F04B0AB6BDE1Q41176091-6F340DA3-846B-4D9A-B174-E8DC330421C2Q41681618-ED82E533-C185-4433-9BF7-CDF9095F1880Q43456283-6478C3A0-DC15-478C-A116-8D480447DA63Q44458418-2A821A0A-0911-47B0-8E98-B0CB86A28347
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Tobias Gerhard
@ast
Tobias Gerhard
@en
Tobias Gerhard
@es
Tobias Gerhard
@nl
Tobias Gerhard
@sl
type
label
Tobias Gerhard
@ast
Tobias Gerhard
@en
Tobias Gerhard
@es
Tobias Gerhard
@nl
Tobias Gerhard
@sl
prefLabel
Tobias Gerhard
@ast
Tobias Gerhard
@en
Tobias Gerhard
@es
Tobias Gerhard
@nl
Tobias Gerhard
@sl
P106
P21
P31
P496
0000-0002-8598-5771